Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Canaccord Genuity 42nd Annual Growth Conference (August 2022)
31 slides from Angiodynamics's conference presentation, Aug 10, 2022
Slide 1: Canaccord Growth Conference
08 | 10 | 2022 ANGIODYNAMICS Canaccord Growth Conference Stephen Trowbridge, EVP & CFO 1
Slide 2: Notice Regarding Forward-Looking Statements
2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business stra
Slide 3: Focused Transformation: U.S. Total Addressable Markets
3 FOCUSED TRANSFORMATION U.S. Total Addressable Markets FY2021 Launch of the Auryon System gives us access to the peripheral atherectomy market $3.0B 2-5% Mkt CAGR $6.0B 3-7% Mkt CAGR $8.0B 3-7% Mkt CAGR FY2023 Planned Thrombectomy & NanoKnife System portfolio additions & new indications increase ma
Slide 4: Med Device and Med Tech positioning
4 MED DEVICE Maintain Positioning Solid Tumor Irreversible Electroporation Peripheral Arterial Disease MED TECH Invest for Growth Thrombus Management
Slide 5: Thrombus Management
THROMBUS MANAGEMENT MED TECH
Slide 6: Deep Vein Thrombosis and Pulmonary Embolism market
$80M $2.1B $1.8B Deep Vein Thrombosis Pulmonary Embolism PE A blood clot that forms in a deep vein, usually the leg, groin or arm A DVT breaks free from a vein wall and travels to the lungs blocking some or all of the blood supply Stages of Clot Clot in Transit (traveling through the heart) Clot in
Slide 7: The Difference: AngioVac System
The Difference The AngioVac System allows for the continuous aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous system Utilizing a self-expanding, nitinol reinforced funnel tip Simultaneously reinfusing the patient’s own filtered blood to limit procedural blood
Slide 8: Control Features for Handle & Cannula
Control Features for Handle & Cannula SYRINGE BARREL Aspirate between 10 & 30cc / pull VOLUME LIMITING SWITCH Allows tailored aspiration volume VACUUM LOCK Allows for continuous aspiration When engaged in clot MANUAL ASPIRATION HANDLE Controlled, single-hand design MULTIPLE TIP ANGLES 00, 200, 850,
Slide 9: Addressable Markets
9 Addressable Markets Pulmonary Embolism (PE) $1.6B TAM AlphaVac F18 Isolated Inferior Vena Cava (IVC) Thrombus $400M TAM AlphaVac F22, F18 Iliofemoral Deep Vein Thrombosis (DVT) $1.7B TAM AlphaVac F14 TAMs: Management estimate & industry sources *AlphaVac F1420 is not cleared by the Food and Drug A
Slide 10: Peripheral Atherectomy
PERIPHERAL ATHERECTOMY MED TECH
Slide 11: Peripheral Atherectomy US Addressable Markets & Competitive Landscape
63% 37% $760M Over 8 Million1 Americans Suffer from P AD Over 150,000 Limbs2 are Lost Every Year because of PAD 50% Mortality Rate2 Associated with PAD after Limb Loss PERIPHERAL ATHERECTOMY US Addressable Markets & Competitive Landscape 3. Peripheral Vascular Devices Medtech 360 Market Analysis US
Slide 12: Auryon System
2.35 mm Aspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR) 2.0 mm Aspiration capability and indicated for Peripheral Atherectomy and ISR 1.5 mm Indicated for Peripheral Atherectomy Why wavelength matters Each type of tissue interacts differe
Slide 13: Irreversible Electroporation
IRREVERSIBLE ELECTROPORATION MED TECH 13
Slide 14: NanoKnife: Innovation Doctors Need
INNOVATION DOCTORS NEED Expands treatment options and help preserve patient's quality of life DECELLULARIZATION Destroys targeted tissue with precise treatment margins.1,2 PROBE PLACEMENT NanoKnife can be confidently used in all segments of an organ.1,2 NON-THERMAL Spares vital structures by retaini
Slide 15: NanoKnife System 2022 Total Addressable Market
$1.6B 15 21%1,2 9%1,2 PROSTATE 70%1,2 2022 Total Addressable Market (TAM) PANCREAS LIVER THE NANOKNIFE SYSTEM Estimated # of US Patients Diagnosed in 20221 Liver 41,260 Pancreas 62,210 Prostate 268,490
Slide 16: Prostate Initiative
Prostate cancer (PCa) is the only solid tumor without a standardized local treatment option1 Advances in genetics, imaging, and methodology support a local treatment option for PCa2 But existing technology has less than ideal outcomes for cancer control and quality of life3,4 16 Approximately 100,00
Slide 17: PRESERVE Prostate IDE
17 PRESERVE Prostate IDE 37 SUO-CTC US sites responded to Call for Sites 20 Sites selected, focused on geographic and demographic diversity, high-volume focal therapy institutions 118 Intermediate-risk patients to be enrolled through 1-year follow up SUO-CTC is a clinical research investigator netwo
Slide 18: Technology Platform Pipeline
18 TECHNOLOGY PLATFORM PIPELINE
Slide 19: Med Tech Platform Expansions
Med Tech Platform Expansions Developing our Med Tech platforms exponentially expands our TAMs FY2023 TAM $6B Portfolio Expansion Pulmonary Embolism Left Atrium Coronary Atherectomy* Arterial Thrombectomy European MedTech Platform Expansion* DVT Atherectomy Right Atrium Prostate Med Device Chronic DV
Slide 20: Peripheral Arterial Disease pipeline and TAM
20 Peripheral Arterial Disease (PAD) Atherectomy Arterial Thrombectomy Venous Thrombectomy Coronary Expansion Opportunity ~$1B TAM Medial Calcification Treatment Claims Expansion Opportunity Coronary Artery Disease (CAD) Atherectomy PAD Interoperative Thrombus NEW Indication Received $50M TAM Acute
Slide 21: Venous Thrombectomy pipeline
21 Right Atrium Venous Thrombectomy Pulmonary Embolism Left Atrium Infective Endocarditis (IE) Current Indications $80M TAM Clot in Transit $170M TAM Isolated IVC Current Indications $400M TAM Iliofemoral DVT Current Indication, Optimized 14F w/ retractor in development $1.7B TAM Pulmonary Embolism
Slide 22: Tumor ablation pipeline
22 Prostate Pancreas Liver Salvage FIRE Trial* $119M TAM Intermediate PRESERVE Trial $585M TAM Stage IIB & III Breakthrough Designation & DIRECT Study $60M TAM Tumor Ablation META Data Analysis $114M TAM Funded Development Project Commercially Available Technology and Platform Expansion Pipeline TAM
Slide 23: Financials
FINANCIALS 23
Slide 24: Fourth Quarter and Full-Year Highlights
Fourth Quarter and Full-Year Highlights Q4 FY2022 Q4 FY2021 Change FY2022 FY2021 Change Revenue $86,998 $76,842 13.2% $316,219 $291,010 8.7% Gross Margin 53.4% 55.1% (170 bps) 52.4% 53.9% (150 bps) Net Loss ($6,266) ($19,468) $13,202 ($26,547) ($31,548) $5,001 GAAP EPS ($0.16) ($0.51) $0.35 ($0.68)
Slide 25: Fourth Quarter and Full-Year Highlights
FY21 FY22 235.3 237.5 55.7 78.7 Fourth Quarter and Full-Year Highlights 25 Med Device Med Tech 40.0% growth 6.1% growth Q4 Revenue Growth Q4 FY21 Q4 FY22 Full-Year Revenue Contribution Med Device Med Tech FY21 FY22 41.2% growth 0.9% growth Q4 Revenue Contribution Full-Year Revenue Growth 21% 79% 26%
Slide 26: Fourth Quarter and Full-Year 2022 Results
Fourth Quarter and Full-Year 2022 Results (unaudited) $ in thousands (except per share data) Q4 FY2022 Q4 FY2021 Change FY2022 FY2021 Change Revenue $86,998 $76,842 13.2% $316,219 $291,010 8.7% Med Tech Med Device $22,611 $64,387 $16,150 $60,692 40.0% 6.1% $78,717 $237,502 $55,731 $235,279 41.2% 0.9
Slide 27: Fourth Quarter and Full-Year 2022 Gross Margin Walk
27 Fourth Quarter and Full-Year 2022 Gross Margin Walk Full-Year Fourth Quarter * Start-up costs include installation costs related to the Auryon lasers and costs related to transitioning the manufacturing of AlphaVac to AngioDynamics.
Slide 28: Full-Year 2022 Cash Walk
Full-Year 2022 Cash Walk i>) angiodynamics
Slide 29: Appendix
APPENDIX 29
Slide 30: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 30
Slide 31: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA (1) (2) (3) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write- offs, certain litigation, and other items. Fis
AngioDynamics — Canaccord Genuity 42nd Annual Growth Conference (August 2022) on 6ix